8th Plenary Meeting EHDN 2014 Barcelona: 19-21 settembre 2014 – Report

Annarita Bentivoglio* - Marina Frontali** Si è appena concluso l’ottavo meeting plenario del Network Europeo per la Malattia di Huntington. Oltre 900 partecipanti: l’incontro più numeroso...

Fatal cellular malfunction identified in Huntington’s disease

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities...

Details emerge of first Huntington’s disease gene therapy clinical trial

UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein...

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of...

EIP Pharma, Inc., a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for...

Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease...

Jul. 1, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger...

Distinct clinical profiles of Huntington’s disease can be associated with two...

Cognitive-motor and psychiatric profiles of Huntington's disease show a different pattern of brain alterations The identification of specific neural signatures can help develop specific biomarkers...

BGU Scientists Duplicate Blood-Brain Barrier Outside the Body

​Scientists can't make a living copy of your brain outside your body. That's the stuff of science fiction. But in a new study, they...

A new molecular mechanism could explain the origins of the depressive...

About 40 % of the affected patients with Huntington’s disease –a neurodegenerative pathology- show depression symptoms, even in early stages before the apparition of...

My Huntington’s disease sister – and a hero who strives for...

Sharon Shaffer is my Huntington’s disease sister – and my hero. Afflicted with progressively worse HD symptoms the past 15 years, San Diego area resident...

uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130...

~ Issued Patents in the U.S. and EU Cover RNA Construct Specifically Designed to Target Highly Toxic Exon1 Protein ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands,...

Smartphone app can help diagnose a rare disease

Team of researchers at Kaunas University of Technology (KTU), Lithuania have created a mobile application, which helps recognise early symptoms of a rare Huntington’s...

The Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will...

Lund Sweden, May 3, 2019 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease...

Nanotubes enable travel of Huntington’s disease protein

upiter, FL - A toxic protein linked to Huntington’s disease can move from neuron to neuron through a nanotube tunnel whose construction is initiated...

UniQure

April 29, 2019 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported...

Fresh Updates from First Huntingtin Lowering Study Publication

Hot off the presses - New publication gives more details about the results of Ionis and Roche's safety study with a Huntingtin-lowering ASO oday saw...

Huntington drug successfully lowers levels of disease-causing protein

An international clinical trial has found that a new drug for Huntington disease is safe, and that treatment with the drug successfully lowers levels...

‘Let’s Talk About Huntington’s Disease’: 2019 HD Awareness Month kicks off

May is Huntington’s Disease Awareness Month. As in past years, the Huntington’s Disease Society of America (HDSA) is encouraging HD families to share their...

When Designing Clinical Trials for Huntington’s Disease, First Ask the Experts:...

Survey finds most individuals in the HD community would consider participating in a gene therapy trial, but study design and goals impact their decisions,...

A prescription drug to treat high blood pressure has shown promise...

A common feature of these diseases – collectively known as neurodegenerative diseases – is the build-up of misfolded proteins. These proteins, such as huntingtin...

Comedian Rod Man’s heartfelt speech, Ramona Johnston’s death remind us of...

In his raw, heartfelt speech in February about the devastation of Huntington’s disease in his extended family, comedian Rod “Rod Man” Thompson reminded his...

Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs

April 10, 2019 at 7:00 AM EDT Topline data readout from Huntington’s disease clinical trials now expected by year end 2019 CAMBRIDGE, Mass., April 10, 2019 (GLOBE NEWSWIRE)...

uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for...

~ On Track to Treat First Patient in Phase I/II Study of AMT-130 in 2H19 ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 08, 2019...